Abstract Details

Title Long-Term Tolerability of Tetrabenazine in the Treatment of Hyperkinetic Movement Disorders

Topic

Presentation(s)

Poster/Presentation
Number 129

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Ralf Linker (Uniklinik Erlangen)	Dr. Linker has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Linker has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. The institution of Dr. Linker has received research support from Novartis. The institution of Dr. Linker has received research support from Biogen.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Tatyana R. Gitlevich, MD (WMC/NYMC)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Adam L. Boxer, MD, PhD (University of California, San Francisco)	An immediate family member of Dr. Boxer has received personal compensation for serving as an employee of Kaiser Permanente. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Third Rock. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Transposon. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Oligomerix. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Humana. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Oscotec. Dr. Boxer has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arvinas. Dr. Boxer has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arkuda. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AZTherapeutics. Dr. Boxer has stock in Alector. Dr. Boxer has stock in Arkuda. Dr. Boxer has stock in Arvinas. An immediate family member of Dr. Boxer has stock in AZtherapies. Dr. Boxer has stock in TrueBinding. The institution of Dr. Boxer has received research support from Biogen. The institution of Dr. Boxer has received research support from Eisai. The institution of Dr. Boxer has received research support from Regeneron. The institution of Dr. Boxer has received research support from NIH. The institution of Dr. Boxer has received research support from Bluefield Project. Dr. Boxer has received research support from Rainwater Charitable Foundation. The institution of Dr. Boxer has received research support from Association for Frontotemporal Degeneration.